- Why do ADC and multispecific deals keep climbing when about 82% of those assets are still in Phase I-II?
- Which modalities are taking hold in oncology, CVRM, immunology and inflammation, and neuroscience?
- Where are nucleic acid and cell therapies moving beyond their original areas?
- What do today’s pipeline and marketed mixes suggest the market will look like in five to ten years?
- Which signals, from Phase III readouts to safety warnings, are shaping investment?